The Challenge
David, a 73-year-old with EGFR+ NSCLC, developed resistance to osimertinib. His caregiver, Sarah, sought guidance on next-line treatment options and how to advocate effectively, feeling overwhelmed by the complex medical landscape.
Our Impact
Cancer Commons provided comprehensive guidance on molecular profiling, explaining its crucial role in identifying resistance mechanisms and future treatment targets. We advised on MRD testing for early detection of progression, offered strategies for navigating second opinions with leading specialists, and cautioned against unproven, high-cost therapies. We also provided resources for supportive care and validated Sarah's advocacy.
The Outcome
Sarah gained clarity and confidence, armed with the language and knowledge to engage effectively with David's care team. The family received a clear roadmap for further testing, treatment planning, and access to expert opinions, leading to more informed and empowered decision-making in a critical phase of David's journey.
